Welcome to our dedicated page for Point Biopharma Global news (Ticker: PNT), a resource for investors and traders seeking the latest updates and insights on Point Biopharma Global stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Point Biopharma Global's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Point Biopharma Global's position in the market.
Lantheus and POINT Biopharma announced that the FDA has granted Fast Track designation for 177Lu-PNT2002, a treatment for metastatic castration resistant prostate cancer (mCRPC). This designation aims to facilitate the drug's development and review process due to the significant unmet medical need in this area. The therapy combines a PSMA-targeted ligand with a beta-emitting radioisotope. Both companies emphasized the importance of this milestone, with Lantheus expressing optimism about working closely with the FDA to advance the therapy. The ongoing Phase 3 SPLASH trial, which assesses the efficacy of 177Lu-PNT2002, has completed enrollment, with top-line results expected in the second half of 2023. Lantheus holds exclusive worldwide commercialization rights for this product.
